Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

The c-Met receptor tyrosine kinase and its ligand HGF (hepatocyte growth factor) have been shown to be involved in angiogenesis, cellular motility, growth, invasion, and differentiation. The role of c-Met/HGF axis in small cell lung cancer (SCLC) has not been reported previously. We have determined the expression of p170(c-Met) precursor and p140(c-Met) beta-chain in seven SCLC cell lines by immunoblotting. We used the SCLC cell line H69, which expressed an abundant amount of c-Met to study the function and downstream effects of c-Met activation. Stimulation of H69 cells with HGF (40 ng/ml, 6-h stimulation) significantly altered cell motility of the SCLC cells with increased formation of filopodia and membrane ruffling, characterized as membrane blebbing, as well as increased migration of the cellular clusters were seen. We have further studied the signal transduction pathways of HGF/c-Met in the H69 cell line. The stimulation of H69 with HGF (40 ng/ml, >24 h, maximal at 1 h) increased the amount of reactive oxygen species formed by 34%. HGF stimulation (40 ng/ml, 7.5-min stimulation) of H69 cells showed increased tyrosine phosphorylated bands identified at M(r) 68,000, 120,000-140,000, and 200,000. Some of these tyrosine-phosphorylated bands were identified as the focal adhesion proteins paxillin, FAK, PYK2, and the c-Met receptor itself. Phospho-specific antibodies show that tyrosines at amino acid (a.a.) 31 of paxillin, and autophosphorylation sites at a.a. 397 of p125FAK, and a.a. 402 of PYK2 are phosphorylated in response to HGF/c-Met signaling. We also demonstrate that the Hsp90 inhibitor geldanamycin, which also affects c-Met, reduced the growth and viability of four of four SCLC cell lines by 25% to 85%, over a 72-h time period. Geldanamycin caused apoptosis of SCLC cells, as well as led to increased levels of Hsp70 but not Hsp90. These results demonstrate that c-Met/HGF pathway is functional in SCLC, and it would be useful to target this pathway toward novel therapy.

[1]  P. Comoglio,et al.  Hepatocyte Growth Factor/Scatter Factor Receptor , 2004 .

[2]  L. Neckers,et al.  Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.

[3]  R. Salgia,et al.  The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells* , 2000, The Journal of Biological Chemistry.

[4]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[5]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  E. Sausville,et al.  The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. , 2000, Cancer research.

[7]  R. Salgia,et al.  Role of the cytoskeletal protein paxillin in oncogenesis. , 2000, Critical reviews in oncogenesis.

[8]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[9]  G. Daley,et al.  The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. , 1999, Blood.

[10]  M. Stella,et al.  HGF: a multifunctional growth factor controlling cell scattering. , 1999, The international journal of biochemistry & cell biology.

[11]  Ze'ev Ronai,et al.  Role of redox potential and reactive oxygen species in stress signaling , 1999, Oncogene.

[12]  R. Simon,et al.  Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Ohnishi,et al.  Involvement of Oxidative Stress in Tumor Cytotoxic Activity of Hepatocyte Growth Factor/Scatter Factor* , 1999, The Journal of Biological Chemistry.

[14]  R. Salgia,et al.  Hematopoietic growth factors signal through the formation of reactive oxygen species. , 1999, Blood.

[15]  Alan Hall,et al.  Rho GTPases Control Polarity, Protrusion, and Adhesion during Cell Movement , 1999, The Journal of cell biology.

[16]  B. Rollins,et al.  Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility , 1999, Oncogene.

[17]  H. Kamata,et al.  Redox regulation of cellular signalling. , 1999, Cellular signalling.

[18]  J. Luketich,et al.  The clinical significance of hepatocyte growth factor for non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[19]  M. Tsao,et al.  The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). , 1998, Oncology reports.

[20]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[21]  Morag Park,et al.  Differential requirement of Grb2 and PI3‐kinase in HGF/SF‐induced cell motility and tubulogenesis , 1997, Journal of cellular physiology.

[22]  P. Srivastava,et al.  Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.

[23]  R. Salgia,et al.  Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL* , 1997, The Journal of Biological Chemistry.

[24]  R. Salgia,et al.  Thrombopoietin induces activation of the phosphatidylinositol‐3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL , 1997, Journal of cellular physiology.

[25]  Y. Suzuki.  [Redox regulation of cellular signaling]. , 1997, Seikagaku. The Journal of Japanese Biochemical Society.

[26]  R. Salgia,et al.  The Related Adhesion Focal Tyrosine Kinase Forms a Complex with Paxillin in Hematopoietic Cells* , 1996, The Journal of Biological Chemistry.

[27]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[28]  W. MacNee,et al.  Role of oxidants/antioxidants in smoking-induced lung diseases. , 1996, Free radical biology & medicine.

[29]  Morag Park,et al.  Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells Requires Phosphatidylinositol 3-Kinase (*) , 1995, The Journal of Biological Chemistry.

[30]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[31]  C. Nobes,et al.  Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. , 1995, Biochemical Society transactions.

[32]  P. Hawkins,et al.  Activation of the small GTP-binding proteins rho and rac by growth factor receptors. , 1995, Journal of cell science.

[33]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[34]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[35]  T. Nakamura,et al.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor , 1992, Molecular and cellular biology.

[36]  G. V. Vande Woude,et al.  Evidence for non-covalent clusters of the c-met proto-oncogene product. , 1992, Oncogene.

[37]  G. V. Vande Woude,et al.  Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.